SPORE 德克萨斯大学 MD 安德森癌症中心

SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病

批准号：

10911713

负责人：

Elizabeth J Shpall

金额：

$91.86万

依托单位：

UNIVERSITY OF TX MD ANDERSON CAN CTR

依托单位国家：

美国

项目类别：

财政年份：

2023

资助国家：

美国

项目状态：

已结题

起止时间：

2023-09-01 至 2024-08-31

来源：

https://reporter.nih.gov/project-details/10911713

关键词：

ATAC-seq Achievement Activated Natural Killer Cell Acute Myelocytic Leukemia Acute leukemia Address Administrator Adoptive Transfer Advocate Aftercare Allogenic Antigens Award Azacitidine B lymphoid malignancy BCL1 Oncogene BCL2 gene Biological Markers Blood Blood Proteins Bone Marrow CAR T cell therapy CASP9 gene CD28 gene CD70 antigen Cancer Center Cancer Center Support Grant Caring Cell Death Cell Differentiation process Cell Line Cell Proliferation Cell Shape Cell Survival Cell Therapy Cell physiology Cells Cellular Stress ChIP-seq Chemoresistance Chromatin Clinic Clinical Clinical Protocols Clinical Trials Collaborations Communication Complement Complex Consultations Cryopreservation Cytarabine Cytoplasm DNA Data Databases Dependence Development Disease Disease remission Doctor of Medicine Dose Doxorubicin Drug Targeting EZH2 gene Electronic Mail Eligibility Determination Endogenous Retroviruses Endowment Engineering Enrollment Ensure Event Exhibits Exposure to FLT3 inhibitor Future Gene Silencing Generations Genes Genetic Transcription Genotype Goals Good Manufacturing Process Grant Hematologic Neoplasms Hematopoietic stem cells Hodgkin Disease Human IL3RA gene In Vitro In complete remission Induction of Apoptosis Infrastructure Institution Institutional Review Boards Interferons Interleukin-15 Laboratories Leukemic Cell Ligands Liposomes Lymphoid Cell Maintenance Marrow Measures Metabolic Metabolism Methods Minority Mitochondrial Electron Transport Complex I Modality Modeling Monitor Morphology Multiple Myeloma Mus Mutation National Cancer Institute Natural Killer Cells Nature Neoadjuvant Therapy Oncogenes Organ Outcome Oxidative Phosphorylation Pathogenesis Pathologic Pathology Patients Pharmaceutical Preparations Phase Phase I Clinical Trials Phase I/II Clinical Trial Phenotype Phosphorylation Inhibition Play Policies Population Postremission Therapy Preclinical Testing Predisposition Preparation Prognosis Progress Reports Proliferating Protein Array Proteomics Protocols documentation Publications Publishing RNA Refractory Regulation Relapse Relaxation Reporting Reproduction spores Research Research Personnel Research Project Grants Residual Neoplasm Residual state Resistance Retrotransposon Risk Safety Sampling Serum Signal Transduction Site Specimen Stem cell transplant Strategic Planning Stress T-Lymphocyte TNF gene Testing Texas Therapeutic Tissues Toxic effect Transcription Elongation Transcription Initiation Translational Research Treatment Efficacy Tumor Antigens Tumor Burden Umbilical Cord Blood United States National Institutes of Health Universities University of Texas M D Anderson Cancer Center Up-Regulation Woman Work acute myeloid leukemia cell adverse outcome antileukemic activity biobank biological adaptation to stress career cell killing cellular transduction chemotherapeutic agent chemotherapy chimeric antigen receptor cohort cost cytopenia design drug development drug testing ds-DNA efficacy testing engineered NK cell experience experimental study first-in-human genetically modified cells graft vs host disease improved improved outcome in vitro activity in vitro testing in vivo inhibitor inhibitor therapy lectures leukemia leukemia relapse leukemia treatment leukemic stem cell lymphoid neoplasm manufacture manufacturing process meetings member mesenchymal stromal cell metabolic fitness mitochondrial fitness mouse model nanomolar neoplastic cell next generation novel novel therapeutics older patient overexpression partial response patient derived xenograft model peripheral blood pharmacodynamic biomarker pharmacologic point of care prevent progenitor programs prospective protein expression receptor recruit relapse patients repository response screening sensor single cell analysis small molecule standard care stem cells success suicide gene symposium synergism targeted therapy trials tool transcriptome sequencing transcriptomics transplantation therapy tumor tumor heterogeneity vector weapons web site

项目摘要

项目成果

Elizabeth J Shpall的其他基金

相似基金

相关文献

中文摘要

翻译

项目摘要

英文摘要

Project Abstract N/A

期刊论文(634)

专著(0)

科研奖励(0)

会议论文

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.

DOI： 10.1158/1078-0432.ccr-16-1904

发表时间： 2017-07-01

期刊：

Clinical cancer research : an official journal of the American Association for Cancer Research

影响因子： --

作者：

[Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang SA, Zhou J, Ai-Atrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes J, Huang X, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M]

通讯作者： Konopleva M

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.

DOI： 10.1007/s10637-011-9660-2

发表时间： 2012-06

期刊：

INVESTIGATIONAL NEW DRUGS

影响因子： 3.4

作者：

[Kantarjian, H. M., Padmanabhan, S., Stock, W., Tallman, M. S., Curt, G. A., Li, J., Osmukhina, A., Wu, K., Huszar, D., Borthukar, G., Faderl, S., Garcia-Manero, G., Kadia, T., Sankhala, K., Odenike, O., Altman, J. K., Minden, M.]

通讯作者： Minden, M.

Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

DOI： 10.1038/s41375-020-0758-4

发表时间： 2020-09

期刊：

Leukemia

影响因子： 11.4

作者：

[Kayser S, Rahmé R, Martínez-Cuadrón D, Ghiaur G, Thomas X, Sobas M, Guerci-Bresler A, Garrido A, Pigneux A, Gil C, Raffoux E, Tormo M, Vey N, de la Serna J, Salamero O, Lengfelder E, Levis MJ, Fenaux P, Sanz MA, Platzbecker U, Schlenk RF, Adès L, Montesinos P]

通讯作者： Montesinos P

Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.

DOI： 10.1038/onc.2009.7

发表时间： 2009-04-09

期刊：

Oncogene

影响因子： 8

作者：

[Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, Perrotti D, Arlinghaus RB]

通讯作者： Arlinghaus RB

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.

DOI： 10.1038/leu.2016.393

发表时间： 2017-09

期刊：

Leukemia

影响因子： 11.4

作者：

[Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN]

通讯作者： Bhalla KN